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Abstract The aim of this study was to evaluate the influ-
ence of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-
dihydrofuran-2-one (LPP1) on nociceptive thresholds in
mouse models of persistent pain. Influence of LPP1 on
motor coordination and its antioxidant capacity in mouse
brain tissue homogenates were also assessed. Pain sensitiv-
ity thresholds in animals treated with LPP1 were established
using 5 % formalin solution in normoglycemic mice and in
streptozotocin (STZ)-treated diabetic mice in the von Frey,
hot plate, innocuous, and noxious cold water tests (water at
10 °C and 4 °C, respectively). Motor deficits were assessed
in the rotarod test, whereas antioxidant capacities were
evaluated using ferric reducing ability of plasma (FRAP)
assay, catalase (CAT), and superoxide dismutase (SOD)
activities. LPP1was antinociceptive in both phases of the
formalin test, in particular, in the late phase (at doses 0.9–
30 mg/kg for 66–99 % vs. control normoglycemic mice) and
in a statistically significant manner increased nociceptive
thresholds in response to mechanical, heat, and noxious cold
stimulation in neuropathic mice (at 30 mg/kg for 274, 192,
and 316 %, respectively vs. diabetic control). LPP1 did not
impair motor coordination of mice in the rotarod revolving
at 6 or 18 rpm. In brain tissue homogenates, it demonstrated
antioxidant capacity in FRAP assay and increased SOD
activity for 63 % (acute administration) and 28 % (chronic
administration) vs. control. No influence on CAT activity
was observed. LPP1 has significant antinociceptive proper-
ties in the formalin model and elevates pain thresholds in
neuropathic mice. It has antioxidant capacity and is devoid
of negative influence on animals' motor coordination.
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Introduction
Neuropathic pain is a debilitating form of chronic pain that
results from dysfunction or damage to the peripheral or
central nervous system (CNS). This type of pain is consid-
ered as a drug-resistant complication that still remains a
serious medical problem worldwide. The term “neuropathic
pain” comprises a variety of painful conditions, including
postamputation pain, painful neuropathies (e.g., painful di-
abetic neuropathy and postherpetic neuralgia), posttraumatic
neuralgia, and others. So far, multiple factors responsible for
development of neuropathic pain have been identified: met-
abolic diseases (e.g., diabetes), neuronal tissue injuries
caused by ischemia, toxicological factors or mechanical
damage to the spinal cord, and others (Nickel et al. 2012;
Woolf and Mannion 1999). Hence, pharmacotherapy used to
relieve neuropathic pain comprises several pharmacological
classes, of which antiepileptic drugs (AEDs), antidepressant
drugs, opioid analgesics, and local anesthetic agents play a
pivotal role (Christoph et al. 2011; Davis 2007; Davis 2010;
Gilron et al. 2009; Miranda et al. 2012; Takeuchi et al. 2007;
Yamama et al. 2010). Despite this, approximately 10–30 %
of patients suffering from neuropathic pain syndromes are
drug resistant (Blackburn-Munro and Erichsen 2005), so
still, there is a great need for seeking new analgesic com-
pounds able to attenuate neuropathic pain episodes.
Many lines of evidence indicate that oxidative stress is
implicated in a variety of disorders, including degenerative
diseases (Kasznicki et al. 2012; Reynolds et al. 2007;
Trushina and McMurray 2007; Uttara et al. 2009), athero-
sclerosis, inflammation (Barton et al. 2007; Reuter et al.
2010; Salvemini et al. 2011), and chronic pain (Janes et al.
2012; Salvemini et al. 2011). Painful diabetic neuropathy is
one of the most serious complications of diabetes in which
the role of oxidative stress has been postulated. Imbalance
between enhanced generation of reactive oxygen and nitro-
gen species and diminished activity of enzymatic and
nonenzymatic antioxidant defenses as a key factor underly-
ing diabetic neuropathy in mammals has been demonstrated
(Di Naso et al. 2011; Pacher et al. 2005).
In our previous studies, we demonstrated significant
antinociceptive, antiinflammatory, and local anesthetic activi-
ties (Salat et al. 2009; Salat et al. 2012a; Salat et al. 2012b;
Więckowski et al. 2012) as well as antioxidant properties (Salat
et al. 2012a; Salat et al. 2012b) of several dihydrofuran-2-one
derivatives, including the 3-[4-(3-trifluoromethyl-phenyl)-
piperazin-1-yl]-dihydrofuran-2-one (LPP1). Observed cell
membrane-stabilizing properties of these derivatives, together
with their antioxidant capacity, suggest that they might be
effective as antiallodynic and antihyperalgesic agents in
diabetes-induced neuropathic pain models.
In the present study, we focus on antinociceptive
activity of the compound LPP1. We evaluate its efficacy
in tonic (formalin) and neuropathic pain models in
normoglycemic and diabetic mice, respectively. In view of
the observed significant antioxidant capacity in 2,2'-azino-bis-
3-ethylbenzothiazoline-6-sulfonic acid (ABTS) radical cation
scavenging assay, we assess influence of LPP1 on selected
markers of oxidative stress in mouse brain tissues (total anti-
oxidant status in ferric reducing ability of plasma (FRAP)
assay, activity of superoxide dismutase (SOD), and catalase
(CAT)). The influence of LPP1 on motor coordination of
diabetic animals in the rotarod test is also presented below.
Materials and methods
Animals and housing conditions
Adult male Albino Swiss (CD-1) mice weighing 18–24 g were
used in behavioral experiments. The animals were kept in
groups of 15 mice in cages at room temperature of 22±2 °C
under light/dark (12:12) cycle and had free access to food and
water before experiments. Ambient temperature of the room
and humidity were kept consistent throughout all tests. For the
experiments, the animals were randomly selected. Each group
consisted of eight to 18 animals per dose and each mouse was
used only once. The mice were allowed to acclimate to holding
cages prior to the test for a minimum of 30 min. The experi-
ments were performed between 8 a.m. and 3 p.m. Behavioral
measures were scored by trained observers blind to experimen-
tal conditions. The animals were killed by cervical dislocation
immediately after the assay. All the procedures were approved
by the local ethics committee of the Jagiellonian University in
Cracow (ZI/595/2011).
Chemicals used in pharmacological tests
Synthesis of the investigated compound, LPP1, was
described previously (Salat et al. 2009). For behavioral
experiments, LPP1, pregabalin (a reference drug in the
neuropathic pain model), and morphine (a reference com-
pound in the formalin test) were suspended in a 0.5 %
methylcellulose solution (Loba Chemie, Germany) and ad-
ministered by the intraperitoneal (i.p.) route 30 min before
the test. Control animals were given an appropriate amount
of vehicle (0.5 % methylcellulose suspension; i.p.) 30 min
before the test. To evaluate antioxidant capacity, LPP1 and
pregabalin were administered in two protocols: acutely (a
single i.p. injection of each compound) and chronically (a
10-day i.p. administration of LPP1 or pregabalin).
Formalin (37 % formaldehyde solution), acetic acid,
hydrochloric acid, toluidine blue, glutaraldehyde (solution
3 % pure), and potassium phosphate were purchased from
Polskie Odczynniki Chemiczne (Poland). Streptozotocin
(STZ), 2,4,6-tripyridyl-S-triazine (TPTZ), and iron (III)
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chloride water solution (FeCl3) were purchased from Sigma-
Aldrich (Poland). Morphine hydrochloride and pregabalin
were provided by Polfa Kutno (Poland) and Tocris
Bioscience (Germany), respectively. Hydrogen peroxide
(H2O2) was provided by Stanlab (Poland) and 0.1 % adren-
aline solution was purchased from Warszawskie Zakłady
Farmaceutyczne Polfa (Poland).
Behavioral testing paradigm
Evaluation of antinociceptive activity and influence on paw
edema formation in the formalin model in normoglycemic mice
In mice, i.p. injection of diluted formalin produces a biphasic
nocifensive behavioral response (i.e., licking or biting the
injected paw). The acute nociceptive (neurogenic) phase lasts
for the first 5 min, whereas the second (inflammatory) phase
occurs between 15 and 30 min after formalin injection. The
formalin test in mice was performed according to Laughlin et
al. (2002). The mice were pretreated with the test compound
or the vehicle and were allowed to acclimate in Plexiglas
observation chambers (20×30×15 cm) for 30 min before the
test. Then, 20 μl of a 5 % formalin solution was injected
intraplantarly into the right hind paw using a 26-gauge needle.
Immediately after formalin injection, the animals were placed
individually into glass beakers and were observed during the
next 30 min. Time (in seconds) spent on licking or biting the
injected paw in selected intervals, 0–5, 15–20, 20–25, and 25–
30 min, was measured in each experimental group and was an
indicator of nociceptive behavior.
To investigate whether or not nociception caused by
formalin is associated with development of edema formation
and to assess influence of LPP1 on edema formation in
formalin-treated mice, paw edema was measured after
intraplantar formalin injection in control and LPP1-treated
animals. For this purpose, immediately after the formalin
test, the mice were sacrificed by cervical dislocation and
both paws were cut at the ankle joint and weighted on an
analytical balance. The difference in weight of the formalin-
treated paw and the weight of the nontreated (control) paw
was compared (Beirith et al. 2002).
Influence on pain sensitivity thresholds in STZ-induced
neuropathic pain model in diabetic mice Induction
and assessment of diabetes
STZ kills insulin-secreting islet cells. To induce type I
diabetes, mice were intraperitoneally injected with STZ (a
single injection of STZ—200 mg/kg) dissolved in 0.1 N
citrate buffer. Age-matched control mice received an equal
volume of citrate buffer. Body weight and blood glucose
level were measured 1 day before (referred to as “day 0”)
and repeatedly 1, 2, and 3 weeks after STZ injection using a
blood glucose monitoring system (Accu-Chek Active,
Roche, France). Blood samples for measurement of glucose
concentration were obtained from the tail vein of the mice.
The animals were considered as diabetic when their blood
glucose concentration exceeded 300 mg/dl (Tanabe et al.
2008) and only these mice (diabetic mice) were used in
subsequent pain tests. In order to follow development of
diabetic neuropathy in STZ-treated mice, time courses of
mechanical and thermal nociceptive thresholds were evalu-
ated for naïve and diabetic animals in the von Frey and hot
plate tests along with blood glucose and body weight mon-
itoring on day 0 as well as 1, 2, and 3 weeks later.
Evaluation of mechanical nociceptive thresholds in diabetic
mice Mechanical hypersensitivity (tactile allodynia) in mice
was assessed using an electronic von Frey unit (Panlab, Spain)
supplied with a single flexible filament applying increasing
force (from 0 to 10 g) against the plantar surface of the hind
paw of the mouse. The nocifensive paw withdrawal response
automatically turned off the stimulus and the mechanical
pressure that evoked the response was recorded.
On the day of the experiment, the mice were placed
individually in test compartments with a wire mesh bottom
and were allowed to habituate for 1 h. After the habituation
period, in order to obtain baseline values, each mouse was
tested three times alternately in each hind paw, allowing at
least 30 s between each measurement. Then, the mice were
pretreated with the test compound or vehicle. Thirty minutes
later, the animals were tested again and mean values for
each mouse were obtained (Tanabe et al. 2008).
Evaluation of pain sensitivity thresholds for cold stimuli in
diabetic mice Cold allodynia and cold hyperalgesia were
assessed as paw withdrawal latencies in response to tempera-
ture, either non-noxious or noxious cold stimulation of hind
paws when dipped in water bath maintained at 10 °C or 4 °C,
respectively (Barriere et al. 2012; Pabreja et al. 2011). After
establishment of baseline values of latency time for each
mouse, the animals were pretreated with the test compound
or vehicle. Thirty minutes later, they were observed until paw
withdrawal or struggle signs with a cutoff time of 30 s were
established to avoid paw tissue damage. Mice not responding
within 30 s were removed from the apparatus and assigned a
score of 30 s. The reaction time was measured two to three
times, with an interval of at least 15 min between the two
measurements to obtain two consecutive values that differed
by nomore than 10%. The hind paws were immediately dried
with cellulose paper to avoid paw cooling between the two
measurements. Final results were expressed as a percentage
according to the following formula:
Cold threshold (%)=100 %− [(mean value in drug-
treated group×100 %)/mean value of the vehicle-treated
group)].
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Evaluation of pain sensitivity thresholds for heat stimuli in
diabetic mice Thermal hyperalgesia was assessed in the hot
plate test as described by Eddy and Leimbach (1953) with
some minor modification. Briefly, mice were treated i.p.
either with the test compound or vehicle 30 min before
placing the animal on the hot plate apparatus (Hot Plate
2AType Omega, Poland). This apparatus has an electrically
heated surface and is supplied with a temperature controller
that maintains the temperature at 55–56 °C. The time until
the animal licked its hind paws or jumped was recorded by
means of a stopwatch. In this assay, the cutoff time was
established (30 s) to avoid tissue damage, and mice not
responding within 30 s were removed from the apparatus
and assigned a score of 30 s.
Formation of degenerative changes (e.g., demyelin-
ation and axonal degeneration), i.e., toxic effects of
STZ within nerves, could explain the differences in pain
sensitivity in experimental mice, including hypoalgesia
due to STZ-induced fiber degeneration. In order to
confirm correctness of results obtained in pain tests,
we investigated whether STZ induced abnormalities
within the nerve structure. For this purpose, we used
the sciatic nerve that is relatively easy to isolate. We
investigated whether these changes (if any) could be
seen in a light microscope. Immediately after the pain
tests, the sciatic nerves were isolated from control
(nondiabetic) mice and STZ-treated mice. The nerves
were fixed in 3 % glutaraldehyde in 0.1 % phosphate
buffer (pH7.4). After dehydration in a graded series of
ethanol followed by acetone, the nerves were embedded
in Epon. Blocks were cut on an ultramicrotome.
Semithin sections were stained with toluidine blue and
examined with a light microscope.
Evaluation of motor impairing properties in diabetic mice
(the rotarod test)
The test was performed according to the method described
by Talarek et al. (2010) with some minor modifications.
Mice were trained daily for 3 days on the rotarod apparatus
(rotarod apparatus, May Commat RR0711, Turkey; rod
diameter: 2 cm) rotating at a constant speed of 18 rpm.
During each training session, the animals were placed on a
rotating rod for 3 min with an unlimited number of trials.
Proper experimentation was conducted at least 24 h after the
final training trial. On the test day, 30 min before the
rotarod test, the mice were intraperitoneally pretreated
with the test compound or vehicle. Then, the animals
were tested on the rotarod, revolving at 6 or 18 rpm.
Motor impairments, defined as the inability to remain
on the rotating rod for 1 min, were measured at each
speed and were expressed as the mean time to fall off
the rotating rod.
Evaluation of antioxidant capacity
For evaluation of antioxidant capacity of LPP1 and
pregabalin, whole-brain tissues of normoglycemic mice re-
ceiving these compounds at a dose of 30 mg/kg (i.p.) acutely
or chronically (for details, see “Chemicals used in pharma-
cological tests”) were homogenized in 0.05 M potassium
phosphate buffer (pH7.0) to obtain 20 % homogenates. The
homogenates were centrifuged (800×g, 20 min, 4 °C), and
the supernatants were used in all further assays. Protein
concentrations were measured by means of a biochemical
analyzer MaxMat PL (Maxmat, France) using ready-made
reagents and applications from AllMed (Poland).
Determination of total antioxidant status in the FRAP assay
The FRAP assay was used to measure the total antioxidant
effect of LPP1 and pregabalin in mouse brain tissues. The
FRAP method i s based on reduc t ion of fe r r ic
tripyridyltriazine (Fe3+–TPTZ) complex to the ferrous
(Fe2+) form at low pH by the low molecular weight plasma
antioxidants. Reduced Fe2+–TPTZ forms an intense blue
color, with an absorption maximum at 593 nm. Absorption
changes proportionally to antioxidant concentration (Benzie
and Strain 1996). FRAP measurement was performed using
the following reagents: 0.2 mol/l acetate buffer (pH=3.6),
0.01 mol/l TPTZ solution in 0.04 mol/l hydrochloric acid,
and 0.02 mol/l iron (III) chloride water solution (FeCl3).
Briefly, 5 μl of plasma along with 15 μl deionized water was
added to 150 μl freshly prepared FRAP reagent containing
acetate buffer, TPTZ, and FeCl3 at 10:1:1 ratio. Blank
samples consisted of 20 μl deionized water against plasma.
Absorbance reading was taken after 6-min incubation period
using a biochemical analyzer MaxMat PL. Change in ab-
sorption (ΔA) between the sample reading (A) and the re-
agent blank reading (A1) was calculated for each sample and
related to ΔA of a Fe2+ standard solutions tested in parallel.
The calibration curve was prepared with the use of five Fe2+
standard solutions: 0.2, 0.4, 0.8, 1.2, and 1.6 mmol/l for
each set of sample measurements.
Determination of SOD activity
SOD activity was determined by the method described by
Misra and Fridovich (1972) that is based on inhibition of
autooxidation of adrenaline to adrenochrome at alkaline pH.
Briefly, the assay mixture consisted of 240 μl 50 mM car-
bonate buffer (pH10.2), 40 μl of the brain homogenate
supernatant, 10 μl of 0.1 % adrenaline, and 10 μl of
20 mM FeCl3 solution (fivefold diluted in 0.05 M potassium
phosphate buffer pH7.0). The initial absorbance was
recorded after FeCl3 addition and the final absorbance after
2 min. The reaction was followed at 480 nm on the
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biochemical analyzer, MaxMat PL. The control sample
contained 40 μl 0.05 M potassium phosphate buffer (pH
7.0) against the sample homogenate. One unit of SOD
activity was defined as the amount of the enzyme that
caused 50 % reduction in the autooxidation of adrenaline.
The final results were expressed as units per gram of protein.
Determination of CAT activity
CAT activity was evaluated by Aebi method (Aebi 1983)
that is based on reduction of H2O2 to generate H2O and O2.
Activity of the enzyme was determined by measuring the
decrease in absorbance at 240 nm. The reagent mixture was
composed of 30 mM H2O2 in 0.05 M potassium phosphate
buffer (pH7.0). The sample (50 μl) was added to 1 ml of the
reagent mixture. Initial absorbance was recorded after addi-
tion of the sample and final absorbance after 1 min. The
reaction was followed at 240 nm with the aid of the U-
2800A UV/Vis spectrophotometer (Hitachi, Japan). Results
were expressed as units per gram of protein. One unit of
CAT activity is defined as the amount of enzyme
decomposing 1 μmol of H2O2 per minute.
Data analysis
Data analysis of the results was provided by GraphPad
Prism Software (v.5). Numerical results from behavioral
tests are expressed as mean±standard error of the mean
(SEM). Results were statistically evaluated using Student's
t test or one-way analysis of variance (ANOVA), followed
by Tukey's or Dunnett's post hoc comparisons to compare
the results obtained in drug-treated and control groups. Two-
way repeated measures ANOVA, followed by Bonferroni's
comparison were applied for statistical evaluation of time
courses of effects obtained in pharmacological tests. In
every case, p<0.05 was considered significant.
The log-probit method (Litchfield and Wilcoxon 1949)
was applied to establish median effective doses (ED50) for
LPP1 and morphine in the first phase of the formalin test.
Here, the ED50 value is defined as the dose of the investi-
gated compound that reduces the duration of formalin-
induced licking or biting response (i.e., the dose that di-
minishes pain reaction) for 50 % as compared to vehicle-
treated animals.
Results
Antinociceptive activity in the formalin test
in normoglycemic mice
In both phases of the formalin test, LPP1 demonstrated a
highly significant antinociceptive activity (Table 1), reducing
duration of nocifensive responses as compared to vehicle-
treated mice. The ED50 value obtained for this compound in
the first phase of the assay (2.1 mg/kg) was comparable to that
of morphine (3.0 mg/kg). A very pronounced antinociceptive
activity of LPP1 was also observed in the second
(inflammatory) phase of the test, in which this compound
reduced duration of paw licking response from 66 % at
0.9 mg/kg to 99.9 % at 30 mg/kg (significant at p<0.001).
Evaluation of the time course of the antinociceptive ac-
tivity of LPP1 at selected intervals revealed that this com-
pound effectively attenuated the nocifensive response
during the first 5 min of the test. This effect was highly
significant (p<0.001; Fig. 1). Antinociceptive effects ob-
served between 15 and 20 min of the test were not statisti-
cally significant (p>0.05 for each dose tested). A significant
reduction of the licking response was observed in LPP1-
treated mice between 20–25 min (p<0.05) and 25–30 min
(p<0.001 for each tested dose; Fig. 1).
The pilot study that aimed at the evaluation of
antiedematous activity of LPP1 in formalin-treated mice
showed that this compound can attenuate some signs of pe-
ripheral inflammation, being able to reduce edema formation
induced by intraplantar formalin. A main overall effect of
treatment was observed (F[3,28]=73.41; p<0.0001). The in-
jection of 5 % formalin caused a statistically significant in-
crease in the paw weight in control animals (formalin-treated
paw weight: 256.3±8.8 mg vs. nontreated paw weight: 154.7
±2.5 mg; p<0.001). Pretreatment with LPP1 (30 mg/kg; i.p.)
had no effect on the nontreated paw weight but it caused an
11 % and statistically significant (p<0.05) decrease of the
formalin-treated paw weight, reducing the paw edema in-
duced by intraplantar administration of formalin.
Assessment of pain sensitivity thresholds in diabetes-induced
neuropathic pain model
Assessment of diabetes
Measurements of the body weight and blood glucose
level Mean body weight of mice before STZ administration
(day 0) was 23.8±0.4 g, whereas 21 days later, the mean
body weight in diabetic mice was 30.1±0.4 g. This differ-
ence was statistically significant (p<0.001). In control
(normoglycemic) mice, the mean body weight at the same
time point was 38.9±0.6 (p<0.001 vs. day 0 body weight).
A statistically significant increase in mean blood glucose
concentration was observed the first 7 days after STZ ad-
ministration. At this time point, the mean blood glucose
concentration in diabetic mice increased from 130.4±
5.5 mg/dl (day 0—before STZ administration) to 475.5±
39.2 mg/dl (7 days after STZ). In STZ-treated mice, this
high glucose level was maintained almost constant as mea-
sured 14 and 21 days after STZ (474.0±41.3 mg/dl and
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462.5±24.6 mg/dl, respectively). In normoglycemic control
mice, the blood glucose level remained almost unaltered as
compared to day 0 level (day 0: 131.5±5.4 mg/dl; 1 week
later: 133.4±6.9 mg/dl; 2 weeks later: 127.0±6.1 mg/dl; 3
weeks later: 119.3±5.9 mg/dl) (Fig. 2a).
No clear differences in the general structure of the
sciatic nerves were observed in STZ-treated control
(Fig. 3b) compared to control nondiabetic mice (Fig. 3a)
and LPP1-treated diabetic mice (Fig. 3c). It can, therefore, be
assumed that in diabetic mice, the nerves were not
damaged 3 weeks after diabetes induction so the phar-
macological effects obtained in our study were not due
to STZ-induced nerve degeneration with the subsequent
development of hypoalgesia.
Evaluation of mechanical and thermal nociceptive thresh-
olds after STZ injection Pain sensitivity thresholds (i.e.,
development of tactile allodynia and thermal hyperalgesia)
in normoglycemic and diabetic mice were assessed in
course of time using von Frey and hot plate tests. In
diabetic animals, a significant decrease of mechanical no-
ciceptive thresholds was observed the first 14 days after
STZ injection (p<0.001; Fig. 2b). Thermal hyperalgesia
developed earlier, i.e., 7 days after STZ (p<0.01; Fig. 2c).
Avery significant (p<0.001) reduction of pain thresholds for
both tactile and thermal stimuli was observed 21 days after
STZ (Fig. 2b, c), so at this time point, the antinociceptive
activities of LPP1 and the reference pregabalin were
evaluated.
Table 1 Antinociceptive activity of LPP1 and morphine in the formalin test
Compound Dose (mg/kg) Duration of licking
response (s)±SEM
(phase I)
Antinociceptive
activity (%)
ED50 (mg/kg)
(phase I)
Duration of licking
response (s)±SEM
(phase II)
Antinociceptive
activity (%)
Vehicle (0.5 % MC) – 91.2±11.1 – – 133.8±22.6 –
LPP1 0.9 59.2±2.8* 35.1 2.1 (0.8–5.3) 44.9±27.7** 66.4
1.8 55.9±7.5** 38.6 4.5±4.2*** 96.6
7.5 18.4±3.6*** 79.9 1.2±0.8*** 99.1
30.0 15.8±4.8*** 82.7 0.1±0.1*** 99.9
Vehicle (0.5 % MC) – 91.2±11.1 – – 133.8±22.6 –
Morphine 2.1 64.7±12.4* 29.1 3.0 (1.9–4.7) 3.4±1.7*** 97.5
3.0 41.2±5.7** 54.8 18.5±6.6*** 86.1
5.0 25.1±3.9*** 72.5 17.9±8.0*** 86.6
Results are shown as mean time of licking response in phase I (0–5 min after intraplantar injection of 5 % formalin) and in phase II (15–30 min after
formalin injection). Statistical analysis: one-way ANOVA followed by post hoc Dunnett's test: phase I: F[4,26]=18.01; p<0.0001 (LPP1) and
F[3,28]=9.007; p<0.0001 (morphine). Phase II: F[4,26]=14.09; p<0.0001 (LPP1) and F[3,28]=26.17; p<0.0001 (morphine). Statistical signif-
icance compared to MC-treated animals: * p<0.05, ** p<0.01, *** p<0.001
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Fig. 1 Time course of the antinociceptive activity of LPP1 in the
formalin test. Data are shown as mean duration of the licking response
(±SEM) measured at selected intervals: 0–5 min, 15–20 min, 20–
25 min, and 25–30 min. Statistical analysis of the results was
conducted using two-way repeated measures ANOVA, followed by
Bonferroni's multiple comparison. Drug effect: F[4,105]=32.57; p<
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at the same time points: *p<0.05; ***p<0.001
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Influence of LPP1 on mechanical nociceptive thresholds
On the day of measurement in nondiabetic control mice,
mean pain sensitivity threshold for mechanical stimulation
was 3.04±0.2 g (Fig. 2b). STZ injection significantly in-
creased pain sensitivity of experimental animals resulting in
reduction of mechanical nociceptive threshold to 1.98±
0.14 g (baseline value; p<0.001 vs. normoglycemic ani-
mals—Fig. 2b). Both LPP1 and pregabalin induced signif-
icant elevation of pain thresholds in STZ-treated mice
(Fig. 4a) and LPP1 was more efficacious than pregabalin
in this respect.
Influence on cold sensitivity thresholds
Neither LPP1 nor pregabalin affected cold sensitivity thresh-
olds in normoglycemic mice in water maintained at 10 °C
(F[2,22]=0.7747; NS). In STZ-treated animals, LPP1-
induced prolongation of latency time to paw withdrawal (at
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Fig. 2 Time courses of blood glucose levels (a) and the development
of mechanical allodynia (b) and thermal hyperalgesia (c) in
normoglycemic mice and in STZ-treated animals. Statistical analysis
of the results was conducted using two-way repeated measures
ANOVA, followed by Bonferroni's multiple comparison. Blood glu-
cose concentration: drug effect: F[1,42]=392.57; p<0.0001; time ef-
fect: F[3,42]=25.3; p<0.0001; interaction: F[3,42]=26.7; p<0.0001.
***p<0.001 compared to nondiabetic mice. Mechanical allodynia was
evaluated using von Frey test and thermal hyperalgesia was assessed
by means of hot plate test (56 °C). Mechanical nociceptive thresholds:
drug effect: F[1,42]=96.33; p<0.0001; time effect: F[3,42]=28.64;
p<0.0001; interaction: F[3,42]=29.41; p<0.0001. Thermal nocicep-
tive thresholds: drug effect: F[1,42]=80.51; p<0.0001; time effect:
F[3,42]=10.68 p<0.0001; interaction: F[3,42]=17.84; p<0.0001. Sig-
nificance: **p<0.01; ***p<0.001 compared to normoglycemic mice
Fig. 3 Representative semithin cross section of the sciatic nerve of
male normoglycemic mice (a), STZ-treated control (b), and LPP1-
treated diabetic mice (c). Toluidine blue stained
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30 mg/kg: 65 % vs. STZ baseline latency and at 10 mg/kg:
20 % vs. STZ baseline latency) was not statistically signifi-
cant. Pregabalin at 30 mg/kg (i.p.) prolonged the latency time
to cold-induced nocifensive response in diabetic animals
(112 % vs. STZ baseline value; p<0.01) (Fig. 4b).
In the paw immersion test in water at 4 °C in
normoglycemic mice, a main overall effect of treatment was
observed (F[2,29]=10.93; p<0.001). Post hoc analysis re-
vealed that only pregabalin at 30 mg/kg prolonged the latency
time to nociceptive reaction (88% vs. control; p<0.01). Strong
antihyperalgesic effects of both LPP1 and pregabalin were
observed in STZ-treated mice in water maintained at 4 °C
(noxious cold stimulus). A main overall effect of treatment
was observed (F[5,63]=8.456; p<0.0001). Post hoc analysis
showed that LPP1 prolonged the latency time to nocifensive
reaction in diabetic animals (224 % and 294 % for 30 mg/kg
and 10 mg/kg, respectively vs. STZ baseline latency time) in a
statistically significant manner (p<0.01 and p<0.001, respec-
tively). In diabetic animals, pregabalin (30 mg/kg) was also
able to prolong the latency time to pain reaction (258 % vs.
STZ; p<0.001) (Fig. 4c).
Influence on heat nociceptive thresholds
In normoglycemic animals, mean baseline latency time to
nociceptive response was 12.75±0.8 s. The baseline latency
time of STZ-treated animals' response to heat stimulus was
shortened for 28 % (p<0.001 vs. nondiabetic mice) and was
von Frey test
ve
hi
cl
e
S
T
Z
LP
P
1/
30
/S
T
Z
LP
P
1/
10
/S
T
Z
LP
P
1/
1/
S
T
Z
LP
P
1/
0.
5/
S
T
Z
P
G
B
/3
0/
S
T
Z
P
G
B
/1
0/
S
T
Z
P
G
B
/1
/S
T
Z
0
2
4
6
8
10
P
aw
 w
ith
dr
aw
al
 th
re
sh
ol
d 
[g
]
Cold water test (10°C)
ve
hi
cl
e
LP
P
1/
30
P
G
B
/3
0
S
T
Z
LP
P
1/
30
/S
T
Z
LP
P
1/
10
/S
T
Z
P
G
B
/3
0/
S
T
Z
0
10
20
30
La
te
nc
y 
tim
e 
[s
] t
o 
pa
in
 r
ea
ct
io
n
Cold water test (4°C)
ve
hi
cl
e
LP
P
1/
30
P
G
B
/3
0
S
T
Z
LP
P
1/
30
/S
T
Z
LP
P
1/
10
/S
T
Z
LP
P
1/
1/
S
T
Z
LP
P
1/
0.
5/
S
T
Z
P
G
B
.3
0/
S
T
Z
0
5
10
15
20
25
La
te
nc
y 
tim
e 
[s
] t
o 
pa
in
 r
ea
ct
io
n
Hot plate test
ve
hi
cl
e
S
T
Z
LP
P
1/
30
/S
T
Z
LP
P
1/
10
/S
T
Z
LP
P
1/
1/
S
T
Z
LP
P
1/
0.
5/
S
T
Z
P
G
B
/3
0/
S
T
Z
P
G
B
/1
0/
S
T
Z
P
G
B
/1
/S
T
Z
0
10
20
30
La
te
nc
y 
tim
e 
[s
] t
o 
pa
in
 r
ea
ct
io
n
a b
c d
Fig. 4 Influence of LPP1 and pregabalin (PGB) on nociceptive thresh-
olds measured as paw withdrawal thresholds in the von Frey test (a), paw
withdrawal latencies in cold water tests (b, c), and the latency time to pain
reaction in the hot plate assay (d). Von Frey test: statistical analysis: one-
way ANOVA followed by post hoc Dunnett's multiple comparison:
F[4,52]=13.48; p<0.0001 (LPP1) and F[3,44]=19.90; p<0.0001
(pregabalin). Significance compared to STZ-baseline: *p<0.05; **p<
0.01; ***p<0.001. Cold water (10 °C) test: influence of LPP1 and
pregabalin on latency time to pain reaction in normoglycemic mice
(LPP1/30; PGB/30) and in STZ-treated mice (LPP1/30/STZ; LPP1/10/
STZ; PGB/30/STZ). Statistical analysis: one-way ANOVA followed by
Dunnett's multiple comparison: F[3,30]=4.568; p<0.01. Significance
compared to STZ baseline latency value: **p<0.01. Cold water (4 °C)
test: influence of LPP1 and pregabalin on latency time to pain reaction in
normoglycemic mice (LPP1/30; PGB/30) and in STZ-treated mice
(LPP1/30/STZ; LPP1/10/STZ; LPP1/1/STZ; LPP1/0.5/STZ; PGB/30/
STZ). Statistical analysis: one-way ANOVA followed by Dunnett's mul-
tiple comparison test: F[5,63]=8.456; p<0.0001. Significance vs. STZ
baseline latency: **p<0.01; ***p<0.001. Hot plate test: antinociceptive
activity of LPP1 and pregabalin in diabetic mice. Statistical analysis: one
way ANOVA followed by post hoc Dunnett's multiple comparison:
F[4,50]=33.50; p<0.0001 (LPP1) and F[3,41]=8.078; p<0.001
(pregabalin). Statistical significance compared to STZ baseline latency:
*p<0.05; **p<0.01; ***p<0.001. The antinociceptive activity of LPP1
in normoglycemic mice in the hot plate test has already been reported.
(Salat et al. 2009)
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an indicative of hyperalgesia. In diabetic mice, both LPP1
and pregabalin at doses 1–30 mg/kg prolonged the latency
time to jump or lick the hind paw (Fig. 4d).
Influence on motor coordination (rotarod test)
Effect of LPP1 on motor coordination in normoglycemic
mice was reported previously (Salat et al. 2012a). In the
present study, to evaluate whether LPP1 and pregabalin can
cause motor impairments in diabetic animals, the rotarod
test was performed. Neither LPP1 nor pregabalin impaired
animals' motor coordination as demonstrated using rotarod
apparatus revolving at 6 and 18 rpm (Fig. 5a, b).
Antioxidant capacity
In the FRAP assay, a statistically significant antioxidant ca-
pacity of both LPP1 and pregabalin administered as a single
i.p. dose of 30 mg/kg was demonstrated (50.7 % and 28.4 %
vs. vehicle-treated mice, respectively; F[4,44]=9.057; p<
0.0001). Chronic administration of these compounds revealed
no effect (p>0.05) (Fig. 6a).
Both LPP1 and pregabalin administered acutely and
chronically had a very significant influence on SOD activity
in mouse brain tissues (Fig. 6b). A main overall effect of the
treatment was observed (F[4,44]=25.66; p<0.0001).
Influence of LPP1 and pregabalin on SOD activity was
particularly enhanced in acute administration (63.4 % and
87.2 % vs. vehicle-treated mice).
Acute and chronic treatments with LPP1 or pregabalin
had no effect on CAT activity in mouse brain tissues
(F[4,44]=2.63; p>0.05). In LPP1-treated mice (acute ad-
ministration), the activity of CAT remained similar to that of
control animals (850.2±55.3 U/g of protein vs. 846.6±
142.9 U/g of protein, respectively). Chronic administration
of LPP1 increased the activity of CAT (1,175±100.9 U/g of
protein); however, these results compared to control values
were not statistically significant (Fig. 6c).
Discussion
In this paper, an extended investigation regarding the
antinociceptive activity of LPP1 in tonic (formalin) and
neuropathic pain models as well as its antioxidant capacity
are demonstrated. Here, we show that LPP1 significantly
influences pain sensitivity thresholds in persistent pain
models and has antioxidant properties in mouse brain
homogenates.
In our previous studies (Salat et al. 2009; Salat et al.
2012a), we demonstrated that LPP1 is a very effective
antinociceptive and local anesthetic compound in rodent
models of acute pain (hot plate and writhing tests, capsaicin
and glutamate pain models in mice) and local anesthesia in
mice and guinea pigs. Both central and peripheral
antinociceptive mechanisms seem to contribute to LPP1-
evoked antinociception, as indicated by the results obtained
in the hot plate test (a pain model of spinal/supraspinal
origin) and in the writhing test (a model of chemically
induced peripheral pain), respectively.
In the present study, we used the formalin model of
chemogenic pain to further evaluate the antinociceptive
efficacy of LPP1. In rodents, the formalin model reflects
persistent pain that is regarded to be dependent on sensory
C-fiber activation, sensitization within the spinal cord dorsal
horn, and the brain; however, peripheral inflammation is
also an important contributor to this type of pain
(Hunskaar and Hole 1987; Tjølsen et al. 1992; Yashpal
and Coderre, 1998). The compound LPP1 demonstrated a
very strong and statistically significant antinociceptive activ-
ity in both phases of this test. The ED50 value obtained for
LPP1 in the first (neurogenic) phase of the test was similar to
that of morphine (2.1 mg/kg vs. 3.0 mg/kg, respectively).
LPP1 was also highly active in the second (late) phase of the
formalin test that is thought to be a pain reaction dependent on
combination of inflammation in peripheral tissues and func-
tional changes in the dorsal horn of the spinal cord (central
sensitization of pain and neuroplasticity of the CNS)
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a bFig. 5 Influence of LPP1 and
pregabalin (PGB) on motor
coordination in diabetic mice
evaluated using rotarod revolving
at 6 rpm (a) or 18 rpm (b).
Statistical analysis: one-way
ANOVA followed by post hoc
Tukey's multiple comparison test:
6 rpm: F[3,28]=0.3216; NS
(LPP1) and F[2,21]=0.7179; NS
(pregabalin); 18 rpm: F[3,28]=
0.6636; NS (LPP1) and F[2,21]=
1.914; NS (pregabalin)
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(Hunskaar and Hole 1987; Pabreja et al. 2011; Tjølsen et al.
1992; Wang et al. 2004).
Several lines of evidence indicate that there is a strong
concentration dependence of nociceptive responses induced
by formalin both in mice and rats. Also, there is evidence
that distinct nociceptive mechanisms might underlie ani-
mals' pain reaction in response to low or high concentrations
of formalin (Yashpal and Coderre 1998). In our study, we
used a 5 % formalin solution. At this concentration of
formalin in the late phase of the test, a significant
dependence of the nociceptive response on peripheral in-
flammatory changes and, to a lesser degree, on central
sensitization is observed (Munro 2009; Yashpal and
Coderre 1998). In our research, this fact was confirmed by
the observed significant degree of edema formation when
5 % formalin solution was injected into control animals'
hind paws and these changes in paw thickness correlated
well with behavioral pain responses of these animals. Our
observation remains in agreement with results reported by
other authors (Yashpal and Coderre 1998) who demonstrat-
ed that 5 %, but not 1 %, formalin produced significant
inflammation and plasma extravasation in peripheral tissues
that were attenuated by high doses of antiinflammatory
drugs (Munro 2009; Yashpal and Coderre 1998).
Regarding the antinociceptive activity of LPP1 in the sec-
ond phase of the formalin test, it can be concluded that this
compound is not only able to attenuate pain symptoms
accompanying formalin-evoked peripheral inflammation
(Taylor et al. 2000) but it can also affect other signs of
inflammation having a weak, albeit statistically significant,
antiedematous activity shown as the decrease of the
formalin-treated paw weight. The antiedematous effect dem-
onstrated previously for some other gamma-butyrolactone
(GBL) derivatives as well (Salat et al. 2012b) is not due to
the influence of LPP1 on the inhibition of proinflammatory
and hyperalgesic prostaglandin E2 synthesis (Sałat et al.
2012c), so the underlying mechanism for this activity seems
to be distinct from that of nonsteroidal antiinflammatory
drugs and requires further studies.
Diabetic mice with symptoms of mechanical allodynia
and thermal hyperalgesia were used as a model of chronic
pain that may reflect painful diabetic neuropathy in humans
(Anjaneyulu and Chopra 2004; Obrosova 2009). In the
present study, mice injected with STZ exhibited significant-
ly increased plasma glucose levels, urine output, and de-
creased body weight gain compared to their normoglycemic
littermates and these effects were observed as early as the
first week after STZ administration. In our research, a sig-
nificant decrease of pain thresholds with the subsequent
development of thermal hyperalgesia and tactile allodynia
were observed in the first 7 and 14 days after STZ, respec-
tively. Conflicting data have been accumulated regarding
the nociceptive thresholds, in particular, for thermal stimuli
in STZ diabetic model of pain. These differences can be
explained, in part, by the kind or intensity of thermal stimuli
as well as the duration of diabetes (Obrosova 2009; Ulugol
et al. 2012). For the above-mentioned reasons, in our study,
pain sensitivity tests were performed 21 days after STZ
administration to avoid development of hypoalgesia that
often occurs during the advanced phase of diabetic process
(Ulugol et al. 2012) in STZ-diabetic animals with longer
term (≥12 weeks) diabetes (Obrosova 2009). Lack of visible
degenerative changes in the general structure of the sciatic
FRAP
ve
hi
cl
e
LP
P
1/
ac
ut
e
LP
P
1/
ch
ro
ni
c
P
G
B
/a
cu
te
P
G
B
/c
hr
on
ic
0.0
0.5
1.0
1.5
A
nt
io
xi
da
nt
 c
on
ce
nt
ra
tio
n
[m
m
ol
/l]
Superoxide dismutase
ve
hi
cl
e
LP
P
1/
ac
ut
e
LP
P
1/
ch
ro
ni
c
P
G
B
/a
cu
te
P
G
B
/c
hr
on
ic
0
1000
2000
3000
4000
C
on
ce
nt
ra
tio
n
[U
/g
 p
ro
te
in
]
Catalase
ve
hi
cl
e
LP
P
1/
ac
ut
e
LP
P
1/
ch
ro
ni
c
P
G
B
/a
cu
te
P
G
B
/c
hr
on
ic
0
500
1000
1500
C
on
ce
nt
ra
tio
n
[U
/l]
a
b
c
Fig. 6 Antioxidant effects of LPP1 and pregabalin (PGB) measured as
total antioxidant capacity in the FRAP assay (a), superoxide dismutase
activity (b), and catalase activity (c) in mouse brains. Statistical anal-
ysis: one-way ANOVA followed by Dunnett's multiple comparison
test. Significance vs. methylcellulose-treated mice: *p<0.05; **p<
0.01; ***p<0.001
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nerve of diabetic animals at the time point at which we
carried out behavioral tests was proven under a light micro-
scope, so the effects observed in behavioral tests (lowering
of nociceptive thresholds in baseline measurement and ele-
vation of pain thresholds induced by LPP1) cannot be at-
tributed to STZ-induced hypoalgesia.
We showed that in diabetic mice, LPP1 significantly
elevated pain reactivity thresholds for mechanical and ther-
mal (noxious cold and heat) stimuli. However, it is worth
noting that increases in paw withdrawal thresholds and
prolonged latency times to pain reactions are only apparent-
ly beneficial effects. These high efficacies of LPP1 and, to a
lesser degree, also pregabalin may be potentially harmful.
Nociception as a part of mechanical, thermal, or chemical
perception protects the body against potential harm. This
means that maintenance or restoration (e.g., by use of anal-
gesic drugs) of physiological pain sensitivity thresholds is
pivotal to avoid a potential damage to the body. In our
research, the nociceptive thresholds were elevated by
LPP1 far beyond baseline values of untreated control mice
and this effect might be responsible for a diminished pro-
tection against harmful stimuli, either mechanical or ther-
mal. In other words, this effect, mainly observed at doses 10
and 30 mg/kg of LPP1, should rather be interpreted as an
undesirable adverse effect and not a measure of its
antinociceptive efficacy.
An interesting observation from the present study was
that the effect of LPP1 varied depending on the type of
thermal stimulus. No influence of LPP1 on pain thresholds
was observed either in normoglycemic or diabetic mice
subjected to innocuous cold (10 °C). LPP1 induced the
elevation of nociceptive thresholds in diabetic animals
subjected to noxious cold (water at 4 °C) and noxious heat
(hot plate maintained at 56 °C) and under these circum-
stances, this activity may be potentially harmful. The ob-
served temperature dependence of LPP1 influence on
nociceptive thresholds is hard to explain at present. In view
of the well-known fact that different biologically active
molecules, in particular, thermosensitive channels belonging
to the Transient Receptor Potential family, are involved in
the sensation of heat (mainly TRPV1 channels), innocuous
cold (TRPM8 channels), and noxious cold (TRPA1 chan-
nels) (Salat et al. 2013b), this fact is an interesting matter for
further studies.
The LPP1-induced elevation of pain thresholds observed
in the present experiment can be confidently attributed to its
action within nociceptive circuits and these effects are not
due to sedation or motor dysfunction. These results support
our earlier findings that showed that LPP1 produces
antinociception in several pain models (Salat et al. 2009;
Salat et al. 2012a). The mechanisms explaining this activity
in diabetic mice are not fully understood. In our previous
studies, we showed that LPP1 had no affinity for GABAA,
opioid μ, and serotonergic 5-HT1A receptors (Salat et al.
2012a), but it possessed potent membrane-stabilizing prop-
erties demonstrated in rodent models of local anesthesia
(Salat et al. 2009). Here, the observed LPP1-induced in-
creases in pain thresholds considerably over the thresholds
of healthy controls might be due to its potent membrane-
stabilizing activity shown previously that might also be an
unwanted side effect, as it can enhance, typical for diabetes,
subjective symptoms of the disease, such as paw numbness,
sensation of rigidity, paresthesia, or heaviness in the sole
upon walking. Although the rotarod test did not reveal any
impairment of motor functions in diabetic mice, the inci-
dence of the above-mentioned disorders cannot be excluded.
To gain further insight into mechanisms that could po-
tentially contribute to the observed pharmacological effects
of LPP1, in the present study, we have estimated this com-
pound's influence on the activity of selected enzymatic
markers of the oxidative stress: SOD and CAT in mouse
brain tissues. Accumulating data indicate that reactive oxy-
gen species are implicated in nociceptive responses and
central sensitization of pain (Janes et al. 2012; Salvemini
et al. 2011), in particular, chronic inflammatory (Wang et al.
2004) and neuropathic pain types (Kasznicki et al. 2012;
Little et al. 2012) both in animals and humans. Available
data from numerous studies show that targeting nitrosative
and oxidative stress can be beneficial as a way to treat
neuropathic pain syndromes and diminish central sensitiza-
tion of pain (Janes et al. 2012; Pacher et al. 2005; Salat et al.
2013a; Salvemini et al. 2011; Salvemini and Neumann
2010). Sharma et al. (2006) showed that superoxide and
nitric oxide are key mediators of glucose-induced oxidative
injuries and they observed a marked increase in the whole
brain nitrite levels in diabetic animals.
In recent years, much attention has been paid to the role
of SOD, an enzyme catalyzing dismutation of superoxide
radicals (McCord and Fridovich 1969), in suppression of
inflammatory and neuropathic pain (Janes et al. 2012; Little
et al. 2012; Wang et al. 2004). It is well appreciated that the
superoxide anion formed during hyperalgesia states plays a
pivotal role in development of pain through direct peripheral
sensitization and is also regarded as a newly identified
mediator of pain (Wang et al. 2004). The centrally released
superoxide anions can play a crucial role in maintenance of
nociception (Wang et al. 2004), whereas inactivation or
decreased activity of mitochondrial manganese SOD is a
critical event in the hyperalgesic response. As a result, a
massive increase of superoxide anions and an indirect in-
crease of peroxynitrite anions occur (Salvemini et al. 2011;
Wang et al. 2004).
The observed strong antinociceptive activity in the sec-
ond phase of the formalin test and the elevation of pain
sensitivity thresholds in the STZ model of neuropathic pain
implicate that antioxidant capacity of LPP1 might, at least in
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part, contribute to its pharmacological properties, including
efficacy in some rodent pain models. Our earlier studies
regarding the antioxidant capacity of LPP1 proved its high
ABTS radical cation-scavenging properties (Salat et al.
2012a). The results from the present research confirm that
LPP1 has antioxidant activity in tissues.
In conclusion, the significant antinociceptive efficacy of
LPP1 in acute and tonic pain models in rodents as well as its
ability to elevate nociceptive thresholds in the diabetic neu-
ropathic pain model indicate an interesting lead structure in
the search for new analgesic agents active in a wide range of
painful conditions, provided carefully selecting dose ranges
that maintain or restore physiological nociceptive thresholds.
The pharmacological activity of LPP1 in mice, together with
the antioxidant effect of this compound, in particular, its
influence on SOD activity, is interesting for further studies.
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